Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
128.4 USD | +1.36% | +3.24% | +3.45% |
Apr. 30 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 67% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 72.16 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.45% | 50.37B | B- | ||
-3.79% | 184B | C+ | ||
-0.84% | 107B | C | ||
-3.75% | 69.44B | A | ||
+9.04% | 44.82B | B- | ||
+3.40% | 41.53B | B+ | ||
+3.66% | 26.84B | A- | ||
+3.21% | 26.73B | B | ||
+15.23% | 25.71B | A- | ||
-0.03% | 24.34B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.